Literature DB >> 23208222

The motor learning strategy instrument: interrater reliability within usual and virtual reality physical therapy interventions.

Danielle Levac1, Cheryl Missiuna, Laurie Wishart, Carol DeMatteo, Virginia Wright.   

Abstract

PURPOSE: To evaluate and compare the interrater reliability of the Motor Learning Strategy Rating Instrument (MLSRI) within usual and virtual reality (VR) interventions for children with acquired brain injury.
METHODS: Two intervention sessions for each of 11 children (total, 22) were videotaped; sessions were provided by 4 physical therapists. Videotapes were divided into usual and VR components and rated by 2 observers using the MLSRI. A generalizability theory approach was used to determine interrater reliability for each intervention.
RESULTS: Interrater reliability for usual interventions was high for the MLSRI total score (g-coefficient, 0.81), whereas it was low for the VR total score (g-coefficient, 0.28); MLSRI category g-coefficients varied from 0.35 to 0.65 for usual and from 0.17 to 0.72 for VR interventions.
CONCLUSION: Adequate reliability was achieved within ratings of usual interventions; however, challenges related to MLSRI use to rate VR-based interventions require further evaluation.

Entities:  

Mesh:

Year:  2013        PMID: 23208222     DOI: 10.1097/PEP.0b013e3182750c28

Source DB:  PubMed          Journal:  Pediatr Phys Ther        ISSN: 0898-5669            Impact factor:   3.049


  2 in total

1.  Promoting Therapists' Use of Motor Learning Strategies within Virtual Reality-Based Stroke Rehabilitation.

Authors:  Danielle E Levac; Stephanie M N Glegg; Heidi Sveistrup; Heather Colquhoun; Patricia Miller; Hillel Finestone; Vincent DePaul; Jocelyn E Harris; Diana Velikonja
Journal:  PLoS One       Date:  2016-12-19       Impact factor: 3.240

2.  Virtual Reality Aided Therapy towards Health 4.0: A Two-Decade Bibliometric Analysis.

Authors:  Zhen Liu; Lingfeng Ren; Chang Xiao; Ke Zhang; Peter Demian
Journal:  Int J Environ Res Public Health       Date:  2022-01-28       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.